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The Ag85 complex is a 30–32 kDa family of three proteins (Ag85A, Ag85B, and Ag85C),
which all three possess enzymatic mycolyl-transferase activity involved in the coupling of
mycolic acids to the arabinogalactan of the cell wall and in the biogenesis of cord factor. By
virtue of their strong potential to induceTh1-type immune responses, important for the con-
trol of intracellular infections, members of the Ag85 family rank among the most promising
TB vaccine candidate antigens. Ag85A and Ag85B, initially purified from Mycobacterium
bovis bacillus Calmette–Guérin (BCG)/Mycobacterium tuberculosis culture filtrate respec-
tively, induce strong T-cell proliferation and IFN-γ production in most healthy individuals
latently infected with M. tuberculosis and in BCG-vaccinated mice and humans but not
in tuberculosis patients. Members of the Ag85 complex are highly conserved in other
mycobacterial species. Mice and humans infected with Mycobacterium ulcerans or cattle
infected with M. bovis or Mycobacterium avium subsp. paratuberculosis also show strong
T-cell responses to this protein family. Using synthetic overlapping peptides, bio-informatic
prediction programs and tetramer-binding studies, a number of immunodominant CD4+
and CD8+ T-cell epitopes have been identified in experimental animal models as well as in
humans, using proliferation andTh1 cytokine secretion as main read-outs.The results from
these studies are summarized in this review.
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INTRODUCTION
The Ag85 complex is actually a 30–32 kDa family of three pro-
teins (Ag85A, Ag85B, and Ag85C), which each possess enzymatic
mycolyl-transferase activity involved in the coupling of mycolic
acids to the arabinogalactan of the cell wall and in the biogen-
esis of cord factor (1). These proteins are also known for their
capacity to bind to the extracellular matrix proteins fibronectin
and elastin (2, 3). In literature members of the Ag85 complex are
known under different names: MtbAg85A: Rv3804c, P32, FbpA;
Mtb 85B: Rv1886c, 30 kDa antigen, α-antigen, FbpB; Mtb85C:
Rv0129c, FbpC2; M. bovis85A: Mb3834c, MPB44; M. bovis
Ag85B:MPB59; M. bovis bacillus Calmette–Guérin (BCG) 85A:
BCG_3866c; M. ulcerans 85A: MUL4987; Map85A: MAP0216;
Map85B: MAP 1609c.
Members of the Ag85 family are found in all mycobacteria,
and sequence comparisons indicate that the Ag85 gene family
arose by duplication of an ancestral gene, before the emergence
of the actually known mycobacterial species (4). The genes encod-
ing these proteins are not physically linked, but located at distinct
sites on the mycobacterial genome. The genes of Ag85 encode
for a characteristic leader sequence of about 40 aa, which is
cleaved off during export and release of the mature proteins into
mycobacterial culture filtrate (CF). The Ag85A and Ag85B com-
ponents are detected essentially as secreted proteins, whereas the
Ag85C component is more tightly associated with the bacterial
cell wall envelope. The calculated secretion index of the three
proteins reflects this difference in localization (5). The mycolyl-
transferase activity of these proteins generates trehalose dimyco-
late (TDM), an envelope lipid essential for Mtb virulence, and cell
wall arabinogalactan-linked mycolic acids. A novel inhibitor of
Ag85C, 2-amino-6-propyl-4,5,6,7-tetrahydro-1-benzothiophene-
3-carbonitrile (I3-AG85) inhibits Mtb survival in infected primary
macrophages and quantification of mycolic acid-linked lipids of
the Mtb envelope showed a specific blockade of TDM synthe-
sis (6). Members of the Ag85 complex are highly conserved in
other mycobacterial species and mice infected with Mycobacterium
ulcerans or with some non-tuberculous mycobacteria belonging to
the MAIS-group (Mycobacterium avium, M. intracellulaire, and M.
scrofulaceum) show cross-reactive Th1-type immune responses to
Ag85 components purified from BCG CF or produced as recom-
binant E. coli derived proteins (5, 7). By virtue of their strong
Th1-type cytokine inducing potential, members of the tuberculo-
sis Ag85 complex (particularly the Ag85A and Ag85B component)
are among the most promising tuberculosis vaccine candidates
today. Many of the new TB vaccines tested in preclinical and
clinical trials, are composed of Ag85 components, expressed as
recombinant fusion proteins or encoded by recombinant viral
vectors (8, 9).
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AMINO-ACID SEQUENCE ALIGNMENTS OF Ag85A, Ag85B, Ag85C OF
Mtb, AND OF Ag85A OFM. ULCERANS,M. AVIUM SUBSP.
PARATUBERCULOSIS (Map), ANDM. LEPRAE
As shown in Figure 1, amino-acid sequences (aa) of the mature
Ag85A homologs (without their leader sequence) are highly con-
served between mycobacterial species. The three aa essential for
the mycolyl-transferase activity, i.e., Serine in position 125, Glu-
tamic acid in position 230 and Histidine in position 262 are
conserved in all sequences (highlighted in red). Although some
aa stretches are 100% conserved between the different species,
there are small variations (indicated in bold as compared to the
Mtb Ag85A sequence). The aa sequence of Ag85A of Mycobac-
terium bovis and M. bovis BCG (1173P2 strain) is identical to
the aa sequence of the Ag85A component of Mtb (H37Rv) and is
therefore not shown. The Ag85B sequence of M. bovis differs in
one aa from the Ag85B sequence of Mtb: Phe100Leu. On the other
hand, expression levels of these proteins may differ and whereas
Ag85A is the major component in CF of surface-pellicle grown
BCG, Ag85B is the major component in CF from Mtb and Map.
The Ag85C component is found in lesser concentrations in the CF,
as it is localized more internally in the cell wall. In 2000,M. Horwitz
reported that recombinant BCG vaccines expressing the Mtb 30-
kDa (Ag85B) major secretory protein induced greater protective
immunity against tuberculosis than conventional BCG vaccines
in a highly susceptible animal model, i.e., the guinea pig (10).
The rationale for the construction of this recombinant BCG, was
1
85A:FSRPGLPVEY LQVPSPSMGR DIKVQFQSGG ANSPALYLLD GLRAQDDFSG WDINTPAFEW
85B:FSRPGLPVEY LQVPSPSMGR DIKVQFQSGG NNSPAVYLLD GLRAQDDYNG WDINTPAFEW
85C:FSRPGLPVEY LQVPSASMGR DIKVQFQGGG PH..AVYLLD GLRAQDDYNG WDINTPAFEE
Mul:FSRPGLPVEY LQVPSVAMGR NIKVQFQSGG ANSPALYLLD GMRAQDDFSG WDINTPAFEW
MAP:FSRPGLPVEY LQVPSAAMGR DIKVQFQSGG ANSPALYLLD GMRAQDDFNG WDINTPAFEW
Mle:FSRPGLPVEY LQVPSPSMGR DIKVQFQNGG ANSPALYLLD GLRAQDDFSG WDINTTAFEW
61
85A:YDQSGLSVVM PVGGQSSFYS DWYQPACGKA GCQTYKWETF LTSELPGWLQ ANRHVKPTGS
85B:YYQSGLSIVM PVGGQSSFYS DWYSPACGKA GCQTYKWETF LTSELPQWLS ANRAVKPTGS
85C:YYQSGLSVIM PVGGQSSFYT DWYQPSQSNG QNYTYKWETF LTREMPAWLQ ANKGVSPTGN
Mul:YYQSGISVAM PVGGQSSFYS DWYNPACGKA GCTTYKWETF LTSELPQYLS ANKGVKPTGS
Map:YNQSGISVAM PVGGQSSFYS DWYKPACGKA GCTTYKWETF LTSELPQYLS AQKQVKPTGS
Mle:YYQSGISVVM PVGGQSSFYS DWYSPACGKA GCQTYKWETF LTSELPQYLQ SNKQIKPTGS
121
85A:AVVGLSMAAS SALTLAIYHP QQFVYAGAMS GLLDPSQAMG PTLIGLAMGD AGGYKASDMW
85B:AAIGLSMAGS SAMILAAYHP QQFIYAGSLS ALLDPSQGMG PSLIGLAMGD AGGYKAADMW
85C:AAVGLSMSGG SALILAAYYP QQFPYAASLS GFLNPSEGWW PTLIGLAMND SGGYNANSMW
Mul:GVVGLSMAGS SALILAAYHP DQFVYSGSLS ALLDPSQGIG PSLIGLAMGD AGGYKASDMW
Map:GVVGLSMAGS SALILAAYHP DQFVYAGSLS ALLDSSQGMG PSLIGLAMGD AGGYKAADMW
Mle:AAVGLSMAGL SALTLAIYHP DQFIYVGSMS GLLDPSNAMG PSLIGLAMGD AGGYKAADMW
181
85A:GPKEDPAWQR NDPLLNVGKL IANNTRVWVY CGNGKPSDLG GNNLPAKFLE GFVRTSNIKF
85B:GPSSDPAWER NDPTQQIPKL VANNTRLWVY CGNGTPNELG GANIPAEFLE NFVRSSNLKF
85C:GPSSDPAWKR NDPMVQIPRL VANNTRIWVY CGNGTPSDLG GDNIPAKFLE GLTLRTNQTF
Mul:GPKDDPAWAR NDPMLQVGKL VANNTRIWVY CGNGKPSDLG GDNLPAKFLE GFVRTSNMKF
Map:GPKEDPAWAR NDPSLQVGKL VANNTRIWVY CGNGKPSDLG GDNLPAKFLE GFVRTSNLKF
Mle:GPSTDPAWKR NDPTVNVGTL IANNTRIWMY CGNGKPTELG GNNLPAKLLE GLVRTSNIKF
241
85A:QDAYNAGGGH NGVFDFPDSG THSWEYWGAQ LNAMKPDLQR AL.GATPNTG PAPQGA
85B:QDAYNAAGGH NAVFNFPPNG THSWEYWGAQ LNAMKGDLQS SL.GAG
85C:RDTYAADGGR NGVFNFPPNG THSWPYWNEQ LVAMKADIQH VLNGATPPAA PAAPAA
Mul:FQAAYNAAGG HNAVWNFDDG THSWEYWGAQ LNAMRPDLQH TL.GATPNTG DTQGA
Map:QDAYNGAGGH NAVWNFDANG THDWPYWGAQ LQAMKPDLQS VL.GATPGAG PATAAATNAGN GGGT
Mle:QDGYNAGGGH NAVFNFPDSG THSWEYWGEQ LNDMKPDLQQ YL.GATPGA
FIGURE 1 | Amino-acid sequence alignment ofMtbAg85A,
MtbAg85B,MtbAg85C, and Ag85A sequence ofM. ulcerans,
M. avium subsp. paratuberculosis, andM. leprae. Aa
differences with the MtbAg85A sequence are underlined and
bold. The three aa essential for the mycolyl-transferase activity are
indicated in red.
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among others the sequence difference of Ag85B of Mtb and that
of the M. bovis BCG Tokyo strain (three aa differences Phe100Leu,
Asn245Lys, and Ala246Pro) (11). As already mentioned, Ag85B of
other BCG strains and M. bovis only differ in position 100 from
the sequence of Ag85B of Mtb.
T-CELL EPITOPES OF Ag85 OFM. TUBERCULOSIS /M. BOVIS AND
M. BOVIS BCG (TABLE 1)
Murine studies
M. bovis BCG. The first T-cell epitope mapping of Ag85A was
performed 20 years ago in seven different mouse strains vacci-
nated with live M. bovis BCG (12). Twenty-eight overlapping
20-mer peptides covering the complete mature 295-amino-acid
(AA) protein were synthesized. Significant interleukin-2 (IL-2)
and gamma interferon (IFN-γ) secretion was measured following
in vitro stimulation of spleen cells with these peptides. H-2d hap-
lotype mice (BALB/c and DBA/2) reacted preferentially against
the amino-terminal half of the protein, i.e., against peptide 5 (aa
41–60) and especially against peptide 11 (aa 101–120), which con-
tains a predicted I-Ed binding motif. H-2b haplotype mice, on
the other hand, reacted against peptides from both amino- and
carboxy-terminal halves of the protein, peptide 25 (aa 241–260)
and peptide 27 (aa 261–280) being the most potent stimulators of
IL-2 and IFN-γ production. Finally, CBA/J (H-2k) and major his-
tocompatibility complex class II mutant B6.C.bml2 mice, carrying
a mutant I-Abml2 allele on an H-2b background, reacted only very
weakly to the 85A peptides. (12).
M. tuberculosis H37Rv. BALB/c and C57BL/6 mice were
infected intravenously with Mycobacterium tuberculosis H37Rv
and Th1-type spleen cell cytokine secretion was analyzed in
response to purified Ag85A, Ag85B, and Ag85C components
and synthetic overlapping peptides covering the three mature
sequences (13). Tuberculosis-infected C57BL/6 mice reacted
strongly to some peptides from Ag85A and Ag85B but not from
Ag85C and more specifically strong responses were detected
against peptide 25 (aa 241–260) of Ag85A and against the same
sequence of Ag85B (13). This latter peptide region was also iden-
tified by Yanagisawa et al. (14) and TCR-transgenic mice with
MHC class II Ab-restricted CD4+ T-cells expressing TCR α and
β chains for the mycobacterial Ag85B240–254 have been generated
(15). Tuberculosis-infected BALB/c mice reacted only to peptides
from Ag85A: p11 (aa 101–120), p16 (aa 151–160), and p20 (aa
191–210) (13).
PlasmidDNAvaccines/viral vectors encodingAg85A,Ag85B, and
Ag85C of Mtb. Plasmid DNA vaccination is a powerful tool to
identify protective antigens of tuberculosis and to identify immun-
odominant CD4+ and particularly CD8+ T-cell epitopes (16).
BALB/c and C57BL/6 mice were vaccinated intramuscularly with
plasmid DNA encoding the three components of the Ag85 com-
plex. Ag85A and Ag85B encoding plasmids induced a robust Th1
like response to native Ag85 purified from BCG CF, characterized
by elevated levels of IL-2, IFN-γ, and TNF-α. Levels of IL-4, IL-6,
and IL-10 were low or undetectable. Plasmid encoding Ag85C
was only weakly immunogenic. Whereas BALB/c mice reacted
preferentially to the Ag85A component, C57BL/6 mice reacted
to both Ag85A and Ag85B with more or less the same magni-
tude (17). Furthermore, vaccination with plasmid DNA encoding
Ag85A or Ag85B but not Ag85C conferred significant protection
against mycobacterial replication in lungs from C57BL/6 mice
(17). T-cell epitopes could be identified in BALB/c and C57BL/6
mice vaccinated with plasmid DNA encoding Ag85A, Ag85B, and
Ag85C DNA using synthetic peptides spanning the three Ag85
proteins, and the epitope repertoire was found to be broader than
in infected mice (13). Despite pronounced sequence homology, a
number of immunodominant regions contained component spe-
cific epitopes. Thus, BALB/c mice vaccinated against all three Ag85
antigens reacted against the same amino-acid region, 101–120
(already identified in BCG vaccinated and TB infected mice) but
responses were completely component specific. In C57BL/6 mice,
a cross-reactive T-cell response was detected against two carboxy-
terminal peptides spanning amino acids 241–260 and 261–280 of
Ag85A and Ag85B. These regions were not recognized at all in
C57BL/6 mice vaccinated with Ag85C DNA.
T-cell repertoire of BALB/c mice vaccinated with plasmid
DNA encoding Ag85A was broader that of Mtb infected mice
(13, 18). Besides peptide regions spanning aa 11–30 and 191–
210 inducing both IL-2 and IFN-γ responses, three peptides
induced strong IFN-γ but weak to no IL-2 responses. More
detailed analysis of the Ag85A sequence for predicted MHC class
I binding motifs using “human leukocyte antigen (HLA) peptide
motif”(http://www-bimas.cit.nih.gov/molbio/hla_bind/) showed
that these three peptides spanned four predicted CD8+ T-cell epi-
topes (18). The following half-time dissociation scores (reflecting
affinity for the respective MHC class I molecules) were found: aa
61–68 YDQSGLSV: half-time dissociation score 600, predicted Kd;
aa 71–78 PVGGQSSF: half-time dissociation score 390, predicted
Ld; aa 145–152 YAGAMSGL: half-time dissociation score 2000,
predicted Kd; aa 161–168 PTLIGLAM: half-time dissociation score
150, predicted Ld. CTL activity against these peptides was demon-
strated using a 51Cr release assay (Figure 2) and showed cross-
reactive responses against Ag85B for both Kd restricted peptides
(18). A particularly interesting region was identified in peptide
15 spanning aa 141–160, which besides the Kd restricted epitope
145–152 also contains a CD4+ epitope with a predicted Rothbard
and Taylor motif spanning aa 147–154 and an amphipathic stretch
spanning aa 149–157 (according to T sites program) (19).
Immunization with DNA followed by modified vaccinia virus
Ankara strain, both expressing the antigen 85A, induced both
CD4+- and CD8+-T-cell responses in BALB/c mice, directed
against the Kd restricted epitope WYDQSGLSV (aa 60–67) and
the I-Ed restricted epitope TFLTSELPGWLQANRHVKPT (aa 99–
119), respectively (20). DNA priming, followed by a MVA85A
boost induced both CD4+ and CD8+ responses, whereas prim-
ing with MVA followed by a DNA boost only induced CD4
responses. Following immunization with dendritic cells pulsed
with the antigen 85A CD4+- or CD8+-restricted epitope, alone or
in combination, copresentation of both epitopes on the same den-
dritic cell was required for protection, demonstrating that induced
CD8+ T-cells can play a protective role against tuberculosis (20).
A single intranasal, but not i.m., immunization with a recom-
binant replication-deficient adenoviral-based vaccine expressing
Ag85A (AdAg85A) provided potent protection against airway M.
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Table 1 | Summary of immunodominant Ag85T-cell epitopes ofM. tuberculosis.
Infection/vaccination Position Sequence Restriction Host Reference
M. tuberculosis INFECTION
Rv3804c 241–260 QDAYNAGGGH NGVFDFPDSG I-Ab Mouse (18)
Rv1886c 240–254 FQDAYNAAGGHNAVF I-Ab Mouse (14)
Rv3804c 101–120 LTSELPGWLQANRHVKPTGS I-Ed Mouse (18)
Rv3804c 151–170 GLLDPSQAMG PTLIGLAMGD H-2d Mouse (13)
Rv3804c 191–210 NDPLLNVGKL IANNTRVWVY H-2d Mouse (13)
Rv3804c 51–70 WDINTPAFEWYDQSGLSVVM Promiscuous LTBI (23)
Rv3804c 141–160 QQFVYAGAMSGLLDPSQAMG Promiscuous LTBI (23)
Rv1886c 100–117 FLTSELPQWLSANRAVKP Promiscuous LTBI (24, 25)
Rv1886c 91–115 GCQTYKWETFLTSEL Promiscuous LTBI (26)
Rv1886c 193–214 PTQQIPKLVANNTRLWVYCGNG Promiscuous LTBI (26)
Rv0129c 70–79 MPVGGQSSFY HLA-B*35 Human/in silico (29)
Rv0129c 160–168 WPTLIGLAM HLA-B*35 Human/in silico (29)
Rv1886c 224–232 IPAEFLENF HLA-B*35 Human/in silico (29)
Rv3804c/Rv1886c 90–104 AGCQTYKWETFLTSE DPB1*04:01 LTBI (28)
M. bovis BCGVACCINATION
Rv3804c 101–120 LTSELPGWLQANRHVKPTGS I-Ed Mouse (12)
Rv3804c 241–260 QDAYNAGGGH NGVFDFPDSG I-Ab Mouse (12)
Rv3804c 261–280 THSWEYWGAQ LNAMKPDLQR I-Ab Mouse (12)
MPB59 51–70 WDINTPAFEW YYQSGLSIVM Promiscuous Human (32)
MPB59 11–30 LQVPSPSMGR DIKVQFQSGG Promiscuous Human (32)
Mtb PLASMID DNAVACCINATION
Rv3804c 101–120 LTSELPGWLQANRHVKPTGS I-Ed Mouse (13, 18)
Rv1886c 100–117 FLTSELPQWLSANRAVKP I-Ad Mouse (13)
Rv0129c 101–120 LTREMPAWLQANKGVSPTGN H-2d Mouse (13)
Rv3804c/Rv1886c 141–160 QQFVYAGAMSGLLDPSQAMG H-2d Mouse (18)
Rv3804c 191–120 NDPLLNVGKLIANNTRVWVY H-2d Mouse (13)
Rv0129c 191–210 NDPMVQIPRLVANNTRIWVY H-2d Mouse (13)
Rv3804c 241–260 QDAYNAGGGH NGVFDFPDSG I-Ab Mouse (13)
Rv3804c 261–280 THSWEYWGAQ LNAMKPDLQR I-Ab Mouse (13)
Rv3804c 61–68 YDQSGLSV Kd Mouse (18)
Rv3804c/Rv1886c 71–78 PVGGQSSF Ld Mouse (18)
Rv3804c/Rv1886c 145–152 YAGAMSGL Kd Mouse (18)
Rv3804c 161–168 PTLIGLAM Ld Mouse (18)
Rv1886c 145–152 FIYAGSLS HLA-A*0201 HLA-tg (27)
Rv1886c 199–207 KLVANNTRL HLA-A*0201 HLA-tg (27)
PROTEINVACCINATION (Mtb Ag85 COMPLEX)
Rv1886c 11–30 LQVPSPSMGRDIKVQFQSGG HLA-DRA/B1*0302 HLA-tg (27)
Rv3804c 121–145 AVVGLSMAASSALTL Epimer Guinea pigs (11)
Rv3804c 196–215 NVGKLIANNTRVWVYCGNGK Epimer Guinea pigs (11)
Rv1886c 101–122 LTSELPQWLSANRAVKPTGSAA Epimer Guinea pigs (11)
Rv1886c 126–140 SMAGSSAMILAAYHP Epimer Guinea pigs (11)
Rv1886c 261–275 THSWEYWGAQLNAMK Epimer Guinea pigs (11)
M. leprae INFECTION
Rv3804c 11–30 LQVPSPSMGR DIKVQFQSGG Promiscuous Lepromin+ (23)
M. ulcerans PLASMIDVACCINATION
MUL4987 21–40 NIKVQFQSGG ANSPALYLLD H-2b Mouse (39)
MUL4987 61–80 YYQSGISVAMPVGGQSSFYS H-2b Mouse (39)
MUL4987 81–100 DWYNPACGKAGCTTYKWETF H-2b Mouse (39)
MUL4987 240–259 FQAAYNAAGGHNAVWNFDD H-2b Mouse (39)
MUL4987 261–280 THSWEYWGAQ LNAMRPDLQH H-2b Mouse (39)
(Continued)
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Table 1 | Continued
Infection/vaccination Position Sequence Restriction Host Reference
Map ATCC 19698 INFECTION
Rv3804c 241–260 QDAYNAGGGHNGVFDFPDSG I-Ab B6 bg/bg (41)
Rv1886c 241–260 QDAYNAAGGHNAVFNFPPNG I-Ab B6 bg/bg (41)
Rv3804c 261–280 THSWEYWGAQLNAMKPDLQR I-Ab B6 bg/bg (41)
Rv1886c 262–279 HSWEYWGAQ LNAMKGDLQ I-Ab B6 bg/bg (41)
Rv0129c 261–280 THSWPYWNEQ LVAMKADIQH I-Ab B6 bg/bg (41)
Rv0129c 21–40 DIKVQFQGGG PH.AVYLLD I-Ab B6 bg/bg (41)
Rv1886c 145–162 YAGSLSALLDPSQGMGPS Promiscuous Bos taurus (41)
Map PLASMID DNAVACCINATION
Rv3804c 241–260 QDAYNAGGGH NGVFDFPDSG I-Ab B6 (42)
Rv1886c 240–260 FQDAYNAAGGHNAVFNFPPNG I-Ab B6 (42)
Rv3804c 91–110 GCQTYKWETF LTSELPGWLQ I-Ab B6 (42)
Rv1886c 145–162 YAGSLSALLDPSQGMGPS I-Ab B6 (42)
Immunodominant T-cell epitopes of Ag85, as defined in experimental vaccination models and infection (LTBI, latent TB infection).
Amino acids different from aa sequence of MtbAg85A (Rv3804c) are indicated in bold/underlined.
The three aa involved in mycolyl-transferase activity are highlighted in red.
FIGURE 2 | CTL activity against P815 target cells loaded with synthetic
20-mer peptides (overlapping by 10 aa, covering the complete Ag85A
sequence) of spleen cells from BALB/c mice vaccinated with mature
Ag85A DNA. Reproduced from Ref. (18).
tuberculosis challenge at an improved level over that by cutaneous
BCG vaccination. Systemic priming with an Ag85A DNA vaccine
and mucosal boosting with AdAg85A conferred a further enhanced
immune protection, which was remarkably better than BCG vac-
cination. Such superior protection triggered by AdAg85 mucosal
immunization was correlated with much greater retention of Ag-
specific T-cells,particularly CD4 T-cells, in the lung and was shown
to be mediated by both CD4+ (LTSELPGWLQANRHVKPTGS, aa
101–120) and CD8+ (MPVGGQSSF, aa 70–78) T-cells (21).
For H-2b haplotype mice, no MHC class I restricted epitopes
have been identified so far on Ag85A or Ag85B to our knowl-
edge, neither in BCG or plasmid DNA vaccinated nor in TB
infected mice.
Human studies
Tuberculosis. In our first paper on Ag85A (called P32 at that
time), we reported that healthy Mantoux positive volunteers
showed a much stronger lymphoproliferative and IFN-γ response
to this antigen than tuberculosis patients (22). This was the initial
indication that T-cell responses against this protein could con-
fer protection against Mtb. Subsequently, we reported on T-cell
epitope mapping of Ag85A from Mtb using peripheral blood
mononuclear cell (PBMC) cultures from healthy tuberculin-
positive volunteers and from patients with tuberculosis, using
the same synthetic 20-mer peptides of the murine study. Peptide
recognition was largely promiscuous, with a variety of HLA hap-
lotypes reacting to the same peptides. PBMC from all tuberculin-
positive subjects reacted to Ag85A, and the majority proliferated in
response to peptide 6 (amino acids 51–70), peptides 13, 14, and 15
(amino acids 121–160), or peptides 20 and 21 (amino acids 191–
220). PBMC from tuberculosis patients demonstrated a variable
reactivity to Ag85 and its peptides, and the strongest proliferation
was observed against peptide 7 (amino acids 61–80) (23). Nine out
of ten of the tuberculin-positive volunteers in this study reacted
to aa 141–160, precisely the peptide characterized by the presence
of both a CD4+ and a CD8+ epitope in BALB/c mice. In contrast,
the most immunogenic CD4+ peptide of Ag85A for BALB/c mice,
i.e., p11 was not recognized by PBMCs from healthy PPD-positive
humans. However, two reports published in 2000 and 2001 showed
that aa 100–117 of Ag85B is recognized in a similar promiscuous
manner by T-cells from a majority of PPD-positive human vol-
unteers (24, 25). Ag85A differs from Ag85B in three aa in this
region Gly107Gln, Gln110Ser, and His114Ala. Ag85A sequences
from M. ulcerans, M. leprae, Map, and Maa also show strong dif-
ferences as compared to MtbAg85A sequence in this region (see
Figure 1). These aa shifts probably explain the difference in the
human responses to Ag85A and Ag85B, as also in DNA vaccinated
BALB/c mice, IL-2 and IFN-γ responses to region 100–120 are
specific for both Ag85 components (13).
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In 1995, Silver et al. had already assessed the T-cell epitopes of
Mtb Ag85B using blastogenic responses of PBMC from 12 healthy
purified protein derivative-positive subjects to a set of synthetic 15-
mer peptides based on the full 325-amino-acid sequence (leader
sequence included) (26). Seven immunodominant regions were
identified and each subject responded to at least one of the two
most dominant epitopes, which corresponded to aa 91–115 and
aa 193–217. Peptides of these two epitopes induced production of
IFN-γ by sorted CD4+ T-cells.
Human leukocyte antigen-transgenic mice can be a powerful
tool to identify human T-cell epitopes in an experimental mouse
model. In 1998,A. Geluk reported on the identification of an HLA-
class II restricted epitope of Ag85. HLA-DRA/B1*0302 (DR3)
transgenic mice were vaccinated with Ag85 protein, purified from
Mtb CF in Incomplete Freund’s adjuvant (27). Using 20-mer pep-
tides, covering the entire Mtb 85B sequence, they identified one
single peptide epitope in the NH2-terminal region, spanning aa
11–30 (aa 51–70 in the numbering including the signal peptide):
LQVPSPSMGRDIKVQFSGG. This sequence is identical in Ag85A
and Ag85B, but differs in two positions in Ag85C: Pro16Ala and
Ser28Gly. Also in M. ulcerans, Map, and Maa, position 16 has the
shift to Alanine. In M. leprae there is also one aa shift: Ser28Asn.
Whereas most of these studies on human T-cell epitope map-
ping were performed during the mid-nineties, one more recent
paper of Lindestam Arlehamn et al. reported on the memory
phenotype of Mtb-specific CD4+ T-cells, using HLA-class II
tetramers for a peptide shared between Ag85A and Ag85B, i.e., aa
90–104 AGCQTYKWETFLTSE in healthy PPD-positive donors,
latently infected with Mtb (28). Tetramer positive T-cells predom-
inantly consisted of CD45RA−CCR7+ central memory T-cells in
all donors tested, followed by effector memory (CD45−CCR7−)
T-cells. Only a minor fraction appeared to be naïve or effector T-
cells. Interesting to note that this sequence is shared with Ag85A
of M. leprae that there is only Q93T shift in M. ulcerans, Map, and
Maa but that the sequence of Mtb Ag85C differs in five positions.
Less is known on human MHC class I restricted epitopes of
Ag85. Klein et al. reported on a HLA-B*35 restricted CD8+ T-
cell epitope of Ag85C (29). Using reverse immunogenetics, they
tested 23 motif-bearing peptides of the Ag85 complex for bind-
ing to HLA-B*35, one of the most common HLA-B types in
West Africa. Three 9-mer peptides bound with high affinity to
HLA-B*3501. Peptide MPVGGQSSFY (spanning aa 70–79 of the
mature protein), a highly conserved region shared by all three
members of the Ag85 complex of Mtb and also identical in M.
ulcerans, M. avium, and M. leprae. This peptide encompasses an
Ld predicted epitope, recognized by BALB/c mice vaccinated with
pAg85A DNA (see Plasmid DNA vaccines/viral vectors encod-
ing Ag85A, Ag85B, and Ag85C of Mtb) and also an IL-2/IFN-γ
inducing region for C57BL/6 mice vaccinated with pAg85C (13).
Peptide WPTLIGLAM of Ag85C (spanning aa 160–168) with a
W160G change as compared to all other sequences, and a T162S
change in Ag85B, and the three other non-tuberculous mycobacte-
ria. Finally peptide IPAEFLENF of Ag85B (spanning aa 224–232),
with an isoleucine in position 224 shared with Ag85C, and a
leucine in Ag85A of Mtb and the four non-tuberculous mycobac-
teria. WPTLIGLAM stimulated effector cells were able to kill Mtb
or BCG infected macrophages and produced IFN-γ and TNF-α
(30). Interestingly, an Ld restricted epitope spanning the same aa
161–168 (PTLIGLAM) was identified in Ag85A DNA vaccinated
BALB/c mice, which did not cross-react with the corresponding
Ag85B peptide (because of the Thr162Ser shift).
A comprehensive epitope mapping to HLA-A*0101, A*0201,
A*1101, A*2402, B*0702, B*0801, and B*1501 of Ag85B was pub-
lished in 2007 (31). Affinity and half-life (t1/2 off-rate) analy-
sis for individual peptide species on HLA-A and HLA-B mole-
cules revealed binding ranges between 10−3 and 10−7 M. After
selection of the best matches, major histocompatibility complex
class I/peptide tetramer complexes were constructed to measure
the CD8+ T-cell responses directly ex vivo in PBMC derived
from 57 patients with acute pulmonary tuberculosis. Three pat-
terns of (allele-) specific CD8+ recognition were identified: (a)
Focus on one dominant epitope, (b) Co-dominant recognition
of two distinct groups of peptides, and (c) Diverse and broad
recognition of peptides (presented by HLA-A*0201). Peptides
that bound with slow off-rates to class I alleles, that is HLA-
A*0201, were associated with low frequency of CD8+ T-cells in
PBMCs from patients with tuberculosis. HLA-B alleles showed
fast off-rates in peptide binding and restricted high numbers
(up to 6%) of antigen-specific CD8+ T-cells in patients with
pulmonary tuberculosis (31). Functional analysis (in vitro IL-
2 and IFN-γ production) revealed that tetramer-binding T-cells
in PBMCs from these patients were little or not responsive to
the nominal peptide epitope, confirming the notion of a defi-
cient Ag85 specific T-cell response in TB patients. The study
focused on TB patients and not on latently infected subjects,
which could have been more relevant in the context of TB vaccine
development.
M. bovis BCG. In 1994, Roche et al. reported on the T-cell deter-
minants of Ag85B of M. bovis (MPB 59) in BCG vaccinees and TB
patients. The mature 85B protein of M. bovis (MPB59) has a high
degree of amino-acid identity with the M. bovis 85A protein (76%)
and the Mtb 85B (99%) and Mtb85A (76%) proteins. Proliferative
assays with recombinant MPB59 demonstrated that PBMC from
95% of BCG vaccinees and 52% of tuberculosis patients responded
to the whole mature protein. Using a set of synthetic 20-mer pep-
tides, five peptides were found to be recognized in more than half
of the MPB59 responders. The T-cell-reactive regions were essen-
tially identical in the M. bovis and Mtb 85B proteins. Subjects with
a variety of HLA-DR phenotypes responded to a number of these
peptides and there was no difference in the pattern of responses
between BCG vaccinees and TB patients. A promiscuous recog-
nition pattern was observed in response to peptides spanning aa
51–70 (recognized by 87% of the responsive BCG vaccinees and
93% of the responding TB patients) and aa 11–30 (recognized by
73% of the responders). Peptides in the C-terminal region (aa 131–
150 and aa 191–210) were more frequently recognized by patients
than by BCG vaccinees (32). More recently, Finan et al. reported
on 236 healthy Gambian babies vaccinated at birth with M. bovis
BCG (33). Using a whole blood assay 2 months after vaccination,
cytokine analysis showed that 89% of the babies produced Ag85
complex specific IFN-γ responses, albeit that response varied up
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to 10 log-fold within this population and 25 and 31% of the babies
also produced detectable levels of the Th2 cytokines IL-5 and IL-
13, respectively. Unfortunately, T-cell epitopes were not mapped
in this study.
A. Geluk et al. reported on the identification of two HLA-
A*0201 restricted CD8+ T-cell epitopes of Ag85B using pDNA
vaccination encoding Ag85B of HLA-A2/Kb transgenic mice. (34).
HLA-A*0201 is one of the most prevalent class I alleles, with a
frequency of over 30% in most populations. The two peptides
spanned aa 145–152 FIYAGSLS and aa 199–207 KLVANNTRL.
As already mentioned, the first region is also recognized by Kd
restricted CD8+ T-cells of Ag85A/B DNA vaccinated mice. The
second peptide differs from that of Ag85A only in position 201,
with a leucine in the Ag85A and a valine in the Ag85B sequence
(both with a non-polar side chain), change that does not affect
the binding affinity for HLA-A*0201 (34). As precursor frequen-
cies of these cells were low in the periphery of human BCG
vaccinees, restimulation with M. bovis BCG was necessary to
visualize the cells by tetramer staining. Stable human CD8+ T-
cell lines were generated against the two peptides, using CD4
depletion and peptide-pulsed autologous Dcs derived, from HLA-
A*0201+ BCG-responsive donors. These T-cell lines were able
to lyse HLA-A*0201+ peptide-pulsed targets and produced the
pro-inflammatory cytokines IFN-γ and TNF-α. The group of
H. Dockrell also demonstrated Ag85A specific CTL responses
using BCG-specific cell lines generated from PBMC of BCG-
vaccinated donors stimulated for 2 weeks with live M. bovis BCG
in the presence of IL-2 and IL-7 (35). In this study, two HLA-
A*0201 restricted epitopes were identified, one spanning aa 5–13
GLPVEYLQV and the other spanning aa 199–207 KLIANNTRV.
This second peptide spans exactly the same region of Ag85B identi-
fied by Geluk et al., using HLA-A2/Kb transgenic mice, suggesting
the existence of a cross-reactive CTL epitope in this region for
Ag85A and Ag85B.
Leprosy. In 1994, we also reported on T-cell epitope mapping of
MtbAg85A using PBMCs from healthy lepromin-positive volun-
teers and from patients with leprosy. As for tuberculosis, peptide
recognition was largely promiscuous, with a variety of HLA hap-
lotypes reacting to the same peptides. However, despite a 90%
homology between the 85A proteins of M. leprae and Mtb, the
peptides recognized were different. PBMC from lepromin-positive
healthy contacts reacted against peptide 2 (aa 11–30), peptide 5 (aa
41–60), and peptides 25 and 26 (aa 241–270). PBMC from pau-
cibacillary patients reacted preferentially against peptide 1 (amino
acids 1–20) and peptide 5. Multibacillary patients were not reactive
to Ag85 or the Ag85A peptides (23). It is interesting to note that
responses to aa 11–30 were also identified in BCG vaccinees (27,
32). It is well known that BCG vaccination exerts some degree of
protection against leprosy and that a second BCG immunization
can increase this protection (36).
Guinea pigs
Lee and Horwitz reported on T-cell epitope mapping of Ag85A
and Ag85B in outbred Hartley strain guinea pigs, immunized with
the purified Mtb proteins and tested for splenocyte proliferation in
response to a series of overlapping 15-mer peptides spanning the
mature proteins (11). Three of the nine immunoreactive regions
of Ag85B identified in the guinea pigs (aa 101–122, 126–140, and
261–275) overlapped with epitopes predicted by the EpiMer com-
puter program (37). Two immunodominant T-cell epitopes were
identified in Ag85A immunized guinea pigs, spanning aa 121–145
and 196–215, and these regions were also predicted by the EpiMer
program (37).
T-CELL EPITOPES OF Ag85 OFM. ULCERANS
The gene encoding Ag85A from M. ulcerans 5150 (MUL4987)
shares 84.1% amino-acid sequence identity and 91% conserved
residues with the gene encoding Ag85A from Mtb (38) (see
also sequence alignment). We characterized the H-2b restricted
immunodominant T-cell epitopes, using synthetic 20-mer pep-
tides spanning the entire mature sequence of Ag85A from M.
ulcerans and from Mtb (39). M. ulcerans DNA vaccinated mice
reacted against M. ulcerans peptides both from the NH2-terminal
and COOH-terminal part of the protein, whereas Mtb DNA vacci-
nated mice reacted almost exclusively against M. ulcerans peptide
spanning aa 240–259, albeit that its sequence is quite different
from that of Mtb. M. ulcerans DNA vaccinated mice also recog-
nized this peptide very effectively. Responses against the NH2-
terminal peptides spanning aa 61–80 and 81–100 of M. ulcerans
were only observed in M. ulcerans DNA vaccinated mice, indicat-
ing that this NH2-terminal region was responsible for a partial
species-specificity.
T-CELL EPITOPES OF Ag85 OFM. AVIUM SUBSP. PARATUBERCULOSIS
(Map)
The genes encoding the three Ag85 components from M. avium
subsp. paratuberculosis (Map) have been sequenced,and at the pro-
tein level, a 99% sequence identity with M. avium subsp. avium
(Maa) was found, with a single amino-acid residue difference for
each protein: Ag85A: Ser155Pro, Ag85B: Ser120Asn, and Ag85C:
Ileu284Thr for Map vs. Maa. Compared to the mature protein
sequences of M. bovis, Map85A (Map 0216) shares 82%, Map85B
(Map 1609c) shares 86%, and the Map85C (Map 3531c) shares
87% identity (40). Map ATCC 19698 was adapted to grow as a
surface pellicle on synthetic, protein-free Sauton medium supple-
mented with mycobactin J. Comparison of the 4-week-old Map
CF with the protein profile of a 2-week-old Mtb H37Rv CF by
SDS-PAGE indicated that in the region of the Ag85 complex, only
one protein of approximately 30 kDa (presumably Map1609c) was
strongly expressed in Map CF (41).
Cross-reactive CD4+ epitopes of Ag85A, Ag85B, and Ag85C of
Mtb were identified in H-2b mice intravenously infected with Map
ATCC 19698 (Figure 3) (41). Spleen cells from susceptible Map
infected B6bg/bg mice reacted against peptides of Ag85A and Ag85B
from Mtb. These epitopes were the same as those we have previ-
ously identified in B6 mice infected with Mtb or vaccinated with
DNA encoding the Mtb Ag85 components (13). Peptides from
Ag85C were more weakly recognized by spleen cells from Map
infected mice.
Cross-reactive CD4+ epitopes of Ag85A, Ag85B, and Ag85C
were also identified in C57BL/6 mice vaccinated with plasmid
DNA encoding the Map antigens (42). Plasmid DNA encoding
the MapAg85A component induced the strongest IFN-γ response,
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FIGURE 3 | Characterization of cross-reactiveT-cell epitopes of Ag85A,
Ag85B andAg85C inM. avium subsp. paratuberculosis-infected B6bg/bg
mice, using synthetic peptides spanning the mature sequences of
Ag85A,Ag85B, and Ag85C fromMtb. IL-2 (left) and IFN-γ (right) production
was analyzed in 24 and 72-h culture supernatants, respectively, of spleen
cells from a pool of five animals infected intravenously with 3×105 CFU of
Map and stimulated with overlapping synthetic peptides (10µg/ml).
Reproduced from Ref. (41).
whereas DNA encoding MapAg85B and MapAg85C induced about
10-fold lower titers. More or less the same epitopes were recog-
nized by pDNA vaccinated as by Map infected mice. However, and
in contrast to infection, peptide 27 of Ag85A or peptide 27 from
Ag85C were not recognized in mice vaccinated with the respec-
tive DNAs. On the other hand, three new epitopes were identified
in pDNA vaccinated mice that were not recognized in infected
animals: peptide 10 (aa 91–110) on Ag85A, peptide 17 (aa 145–
162) on Ag85B, and the corresponding region of Ag85C covered
by peptides 15–16 (aa 141–170). The strongest Th1 epitope iden-
tified in this study spanned region 241–260 of the Ag85A and
Ag85B sequence. These sequences are very similar to each other,
but – as for M. tuberculosis – the Ag85C sequence is completely
different.
Ag85 specific T-cell epitopes were also mapped in experimen-
tally infected cattle, the target species of Johne’s disease. Five 2-
to 3-week-old calves were infected by the oral route with 10 mg
(108 CFU) of Map (ATCC 19698) cells per day for 10 consecutive
days. (41). Strong proliferative and ex vivo IFN-γ responses against
Ag85, purified from M. bovis BCG CF, could be detected in cattle as
early as 10 weeks after oral Map infection. Synthetic peptides from
the Ag85A and Ag85B components of this complex were strongly
recognized, whereas T-cell responses were weaker against peptides
from the Ag85C protein. A promiscuous T-cell epitope spanning
amino acids 145–162 of Ag85B (identical sequence in M. bovis and
Map) was identified in experimentally infected cattle.
CONCLUDING REMARKS
Members of the Ag85 complex are immunodominant mycobac-
terial antigens, which induce strong Th1-type immune responses
in situations of controlled mycobacterial infection. By virtue of
their role in cell wall integrity and synthesis of cord factor, these
abundantly expressed proteins have long been considered as vir-
ulence factors. On the other hand, because of the strong T-cell
responses they induce, these proteins can also be regarded as a
means of both host and pathogen to reach a state of equilib-
rium, advantageous for both parties. An estimated one third of
the world population is infected with Mtb, an immense reser-
voir for this successful microbe. However, most humans latently
infected with Mtb will never develop the active disease, precisely
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because of the strong elicited T-cell response. A similar scenario
holds true for infections caused by other mycobacteria such as
M. leprae and non-tuberculous mycobacteria from the environ-
ment such as M. ulcerans and various M. avium subspecies. The
MHC class I and MHC class II restricted epitopes of Mtb/M. bovis
Ag85A and Ag85B have been identified in experimental animal
models and in healthy Mantoux positive subjects. In humans,
a small number of dominant T-cell epitopes were found to be
promiscuously recognized by subjects with many different HLA
haplotypes. Also in experimental mouse models (particularly of
H-2d haplotype), the same epitopes have been identified. More
in particular, regions spanning aa 10–30, 60–80, 100–120, 140–
160, and 199–207 of the mature Ag85A and Ag85B span these
IFN-γ/IL-2 inducing Th1/CTL epitopes. The Ag85C component
differs in its sequence from the two other components and over-
all T-cell responses against this third component are lower. The
Ag85C molecules are buried more in the cell wall and hence
may be less accessible for rapid antigenic processing and pre-
sentation to T-cells. It is also possible that because of this less
exposed localization, there has been less evolutionary pressure on
the gene of Ag85C to encode for such immunodominant, promis-
cuous T-cell epitopes. Members of the Ag85 complex are highly
conserved in other mycobacterial species and cross-reactive T-
cell responses against Mtb antigens can be found in M. ulcerans,
Map, and M. leprae infection. Sequence comparisons indicate that
the Ag85A sequences of these three non-tuberculous mycobac-
teria are more similar to the sequence of MtbAg85B than of
MtbAg85A, particularly in aa stretches spanning the immun-
odominant epitope regions. Moreover, expression of the two
components by different mycobacterial species seems to be dif-
ferentially regulated, with a preference for the Ag85B orthologs
in NTM.
Recently, a randomized, placebo-controlled phase 2b trial in
a rural region near Cape Town, South Africa, analyzing safety
and efficacy of MVA85A in infants previously vaccinated with
BCG, showed that the MVA85A boost was well tolerated but
induced only modest cell-mediated immune responses (lower that
responses observed in previous studies in adult BCG vaccinees in
United Kingdom) and furthermore did not augment protective
efficacy of BCG (43). The reasons for this vaccine trial failure are
not clear but conclusions as to the protective nature of Ag85A
should not be taken too hastily. It is important to stress that the
rationale for all BCG boosting strategies is based on the assump-
tion that BCG-induced protection is waning in time through
gradual attrition of BCG-induced T-cells. One could argue that
in the Tameris study, the time between neonatal BCG vaccination
and MVA85A boost was too short to measure effects of waning
immunity. On the other hand, there may be other factors than just
waning that are responsible for the variable efficacy of BCG and
besides magnitude, the quality of the memory response induced
by the BCG vaccine may be insufficient (44). More specifically,
the BCG vaccine is a very poor inducer of CD8+ T-cells, which
are especially important for the control of a latent TB infec-
tion. As BCG vaccination primes almost exclusively for MHC
class II restricted responses, it is obvious that boosting strate-
gies with proteins and even with recombinant viral vectors will
augment preferentially the CD4+ T-cell population. Priming with
plasmid DNA encoding Ag85A can increase the protective efficacy
of BCG in mice as measured in a long term survival study and
this increased efficacy is accompanied by increased Ag85A spe-
cific CD8+ responses (45). More recently, we have shown in an
experimental mouse model and also in a large mammalian species
(Sus scrofa) that the vaccine potential of live BCG can be aug-
mented by coadministration with plasmid DNA encoding PPE44
and Ag85A respectively, as measured by Th1-type cytokine secre-
tion, specific IgG antibodies, as well as specific IFN-γ producing
CD8+ T-cells (46) (Bruffaerts et al. submitted for publication).
These results have provided a proof of concept for a new TB vac-
cine, based on BCG-plasmid DNA combination, approach that
now needs to be tested in non-human primates, the only ani-
mal species in which reactivation of latent Mtb infection can be
monitored properly (47).
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